Moving from peanut extract to peanut components: towards validation of component-resolved IgE tests

Area of Science:

• Allergen immunotherapy
• Immunological diagnostics
• Food allergy research

Background:

• Current allergy serologic testing relies on peanut extracts, but recombinant components offer a more standardized approach.
• Validation of recombinant peanut components requires unbiased patient selection criteria.
• Natural peanut extracts may under-represent certain allergens due to extraction limitations.

Purpose of the Study:

• To evaluate the suitability of recombinant peanut allergens for allergy serologic testing.
• To assess the impact of extraction pH on the representation of allergens in peanut extracts.
• To develop criteria for unbiased patient inclusion in studies validating recombinant peanut allergens.

Main Methods:

• Compared IgE reactivity to six recombinant peanut allergens versus natural peanut proteins (neutral/low pH extracts).
• Utilized plasma samples from 64 peanut-allergic children (42 reactors, 22 nonreactors via food challenge).
• Investigated the hypothesis that poor extractability of basic allergens (e.g., Ara h 9) at neutral pH leads to under-representation.

Main Results:

• IgE reactivity to recombinant components did not fully explain extract reactivity in some patients.
• Recombinant components showed stronger reactivity than extract in 11 samples, mainly due to low Ara h 8 extract reactivity.
• Ara h 9 reactivity was lower than other basic proteins, with some losing IgE binding post-immunoblotting.

Conclusions:

• Conventional peanut extracts are deficient in significant IgE-binding components.
• Patient inclusion for validation studies should use improved peanut reagents to avoid bias.
• Effective reagents are essential for detecting IgE to specific allergens and judging clinical relevance.